Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | PHGDH | O43175 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LSS | P48449 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498229 | 0.89 | HPGD (0.53) | HPGDHRH3NAMPTCYP3A4CYP2C19 | |
| SCHEMBL23498231 | 0.85 | FABP6 (0.62) | HPGDHRH3NAMPTIDO1TDO2 | |
| SCHEMBL24754466 | 0.85 | GAA (0.47) | GAAHPGDHRH3NAMPTCYP3A4 | |
| SCHEMBL1014002 | 0.79 | HPGD (0.86) | GAAHPGDHRH3PHGDHSMN1; SMN2 | |
| SCHEMBL10468257 | 0.78 | HPGD (0.48) | GAAHPGDHRH3NAMPTPHGDH | |
| SCHEMBL10467940 | 0.78 | HPGD (0.48) | GAAHPGDHRH3NAMPTPHGDH | |
| SCHEMBL22091424 | 0.77 | MEN1 (0.51) | GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL15754906 | 0.77 | PHGDH (0.66) | HPGDNAMPTPHGDHCYP3A4CYP2C19 | |
| SCHEMBL23520519 | 0.76 | CYP17A1 (0.49) | GAAALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9614659 | 0.75 | PHGDH (0.64) | HPGDNAMPTPHGDHCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003658-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-23 | — | — | CN | claimed |
| EP-4073043-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2024-04-03 | — | — | EP | claimed |
| EP-4073043-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | claimed |
| CN-115003658-A | Compounds and their use in the treatment of alpha 1 Use against trypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | claimed |
| WO-2021116706-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | claimed |
| CN-115003658-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-4073043-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-20230102488-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | OXFORD FINANCE LLC | 2023-03-30 | — | — | US | disclosed |
| US-20230102488-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | OXFORD FINANCE LLC | 2023-03-30 | — | — | US | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-4073043-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| CN-115003658-A | Compounds and their use in the treatment of alpha 1 Use against trypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021116706-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116706-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102488-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | SERPINA2, SERPINB1, SERPINH1 | GAA 29/4885HPGD 220/4885HRH3 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.